Insulet International company position statement

Insulet International welcomes the Appraisal publication by the National Institute for Health and Care Excellence (NICE) on Hybrid Closed Loop (HCL) technology and considers it a significant milestone to expanding access to life-changing technology to people living with Type 1 Diabetes (T1D) across England and Wales. 

“It's tremendously exciting that more people with type 1 diabetes living in England and Wales will be eligible to access HCL technology, including Omnipod 5, to help effectively manage their diabetes” says Hjalte Hojsgaard, VP, General Manager of UK, Benelux & DACH at Insulet. “Advancing choice in access to diabetes management technology is critical, and this recommendation from NICE supports that.”

Melanie Littlewood, Senior Director of Value & Access, International said, “We celebrate this important milestone for the diabetes community. Whilst many lives will be positively impacted by these recommendations moving forward, funding will be critical to ensure timely and equitable access for all.”

As a leading medical device company, continually investing in innovations and our ecosystem to create value for health systems and the diabetes community, we look forward to continuing our work with NHS England to support the implementation.   

Omnipod® 5, Insulet’s flagship innovation, was launched to the UK market in June 2023 and integrates the tubeless Pod enhanced with SmartAdjust™ technology with a continuous glucose monitor to automate insulin delivery. Clinical data shows that users stay in automated mode 96% of the time, allowing the system to adjust insulin predictively and eliminating almost all insulin tasks outside of bolusing. Consequently, Omnipod 5 greatly reduces the burden of type 1 diabetes self-management in a simple and advanced package.

NICE guidance published online: https://www.nice.org.uk/guidance/ta943